PDF herunterladen
Exp Clin Endocrinol Diabetes 2020; 128(06/07): 414-422
DOI: 10.1055/a-1108-1456
Mini-Review

Allan-Herndon-Dudley-Syndrome: Considerations about the Brain Phenotype with Implications for Treatment Strategies

Heiko Krude
1   Institute of Experimental Pediatric Endocrinology, Charité - Universitätsmedizin, Berlin, Germany
,
Heike Biebermann
1   Institute of Experimental Pediatric Endocrinology, Charité - Universitätsmedizin, Berlin, Germany
,
Markus Schuelke
2   Department of Neuropediatrics, Charité - Universitätsmedizin, Berlin, Germany
,
Timo D. Müller
3   Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Centre Munich, Germany
5   German Center for Diabetes Research (DZD), Neuherberg, Germany
6   Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, Tübingen, Germany
,
Matthias Tschöp
4   Division of Metabolic Diseases, Technische Universität München, Munich, Germany
5   German Center for Diabetes Research (DZD), Neuherberg, Germany
7   Helmholtz Zentrum München, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Despite its first description more than 75 years ago, effective treatment for “Allan-Herndon-Dudley-Syndrome (AHDS)”, an X-linked thyroid hormone transporter defect, is unavailable. Mutations in the SLC16A2 gene have been discovered to be causative for AHDS in 2004, but a comprehensive understanding of the function of the encoded protein, monocarboxylate transporter 8 (MCT8), is incomplete. Patients with AHDS suffer from neurodevelopmental delay, as well as extrapyramidal (dystonia, chorea, athetosis), pyramidal (spasticity), and cerebellar symptoms (ataxia). This suggests an affection of the pyramidal tracts, basal ganglia, and cerebellum, most likely already during fetal brain development. The function of other brain areas relevant for mood, behavior, and vigilance seems to be intact. An optimal treatment strategy should thus aim to deliver T3 to these relevant structures at the correct time points during development. A potential therapeutic strategy meeting these needs might be the delivery of T3 via a “Trojan horse mechanism” by which T3 is delivered into target cells by a thyroid hormone transporter independent T3 internalization.

Key words

Thyroid hormone transporter - Allan-Herndon-Dudley-Syndrome - pathophysiology


Publikationsverlauf

Eingereicht: 01. Oktober 2019
Eingereicht: 17. Januar 2020

Angenommen: 28. Januar 2020

Artikel online veröffentlicht:
02. April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Grüters A, Krude H. Detection and treatment of congenital hypothyroidism. Nat Rev Endocrinol 2011; 8: 104-113
    CrossrefPubMedGoogle Scholar
  • 2 Aleksander PE, Brückner-Spieler M, Stoehr A-M. et al. Mean high-dose l-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism. J Clin Endocrinol Metab 2018; 103: 1459-1469
    CrossrefPubMedGoogle Scholar
  • 3 Groeneweg S, van Geest FS, Peeters RP et al. Thyroid hormone transporters. Endocr Rev 2019; Im Internet: Im Internet: https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnz008/5637505
  • 4 Groeneweg S, Visser WE, Visser TJ. Disorder of thyroid hormone transport into the tissues. Best Pract Res Clin Endocrinol Metab 2017; 31: 241-253
    CrossrefPubMedGoogle Scholar
  • 5 Bernal J, Guadaño-Ferraz A, Morte B. Thyroid hormone transporters—functions and clinical implications. Nat Rev Endocrinol 2015; 11: 406-417
    CrossrefPubMedGoogle Scholar
  • 6 Verge CF, Konrad D, Cohen M. et al. Diiodothyropropionic Acid (DITPA) in the Treatment of MCT8 Deficiency. J Clin Endocrinol Metab 2012; 97: 4515-4523
    CrossrefPubMedGoogle Scholar
  • 7 Groeneweg S, Peeters RP, Moran C. et al. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: An international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol 2019; 7: 695-706
    CrossrefPubMedGoogle Scholar
  • 8 Dumitrescu AM, Liao X-H, Weiss RE. et al. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (Mct) 8-Deficient mice. Endocrinology 2006; 147: 4036-4043
    CrossrefPubMedGoogle Scholar
  • 9 Trajkovic M, Visser TJ, Mittag J. et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest 2007; 117: 627-635
    CrossrefPubMedGoogle Scholar
  • 10 Müller J, Heuer H. Expression pattern of thyroid hormone transporters in the postnatal mouse brain. Front Endocrinol 2014; 5: Im Internet: https://www.frontiersin.org/articles/10.3389/fendo.2014.00092/full
  • 11 Mayerl S, Müller J, Bauer R. et al. Transporters MCT8 and OATP1C1 maintain murine brain thyroid hormone homeostasis. J Clin Invest 2014; 124: 1987-1999
    CrossrefPubMedGoogle Scholar
  • 12 Gika AD, Siddiqui A, Hulse AJ. et al. White matter abnormalities and dystonic motor disorder associated with mutations in the SLC16A2 gene. Dev Med Child Neurol 2010; 52: 475-482
    CrossrefPubMedGoogle Scholar
  • 13 Azzolini S, Nosadini M, Balzarin M. et al. Delayed myelination is not a constant feature of Allan–Herndon–Dudley syndrome: Report of a new case and review of the literature. Brain Dev 2014; 36: 716-720
    CrossrefPubMedGoogle Scholar
  • 14 Wilpert N-M, Krueger M, Opitz R et al. Spatiotemporal changes of cerebral monocarboxylate transporter 8 expression. Thyroid 2020; accepted
  • 15 López-Espíndola D, García-Aldea Á, Gómez de la Riva I. et al. Thyroid hormone availability in the human fetal brain: Novel entry pathways and role of radial glia. Brain Struct Funct 2019; 224: 2103-2119
    CrossrefPubMedGoogle Scholar
  • 16 López-Espíndola D, Morales-Bastos C, Grijota-Martínez C. et al. Mutations of the thyroid hormone transporter MCT8 cause prenatal brain damage and persistent hypomyelination. J Clin Endocrinol Metab 2014; 99: E2799-E2804
    CrossrefPubMedGoogle Scholar
  • 17 Schwartz CE, Ulmer J, Brown A. et al. Allan-Herndon syndrome. II. Linkage to DNA markers in Xq21. Am J Hum Genet 1990; 47: 454-458
    PubMedGoogle Scholar
  • 18 Allan W, Herndon N, Dudley FC. Some examples of the inheritance of mental deficiency: Apparently sex-linked idiocy and microcephaly. Am J Ment Defic 1944; 4: 325-334
    PubMedGoogle Scholar
  • 19 Schwartz CE, May MM, Carpenter NJ. et al. Allan-Herndon-Dudley Syndrome and the Monocarboxylate Transporter 8 (MCT8) Gene. Am J Hum Genet 2005; 77: 41-53
    CrossrefPubMedGoogle Scholar
  • 20 Holden KR, Zuñiga OF, May MM. et al. X-Linked MCT8 gene mutations: Characterization of the pediatric neurologic phenotype. J Child Neurol 2005; 20: 852-857
    CrossrefPubMedGoogle Scholar
  • 21 Holstege G. Chapter 2 The somatic motor system. In Holstege G, Bandler R, Saper CB. Hrsg Progress in Brain Research. Elsevier; 1996: 9-26 Im Internet: http://www.sciencedirect.com/science/article/pii/S0079612308618567
    Google Scholar
  • 22 Trošt M. Dystonia update. Curr Opin Neurol 2003; 16: 495-500
    CrossrefPubMedGoogle Scholar
  • 23 Wichmann T, Bergman H, DeLong MR. Basal ganglia, movement disorders and deep brain stimulation: Advances made through non-human primate research. J Neural Transm 2018; 125: 419-430
    CrossrefPubMedGoogle Scholar
  • 24 Pavone P, Praticò AD, Pavone V. et al. Ataxia in children: Early recognition and clinical evaluation. Ital J Pediatr 2017; 43: 6
    CrossrefPubMedGoogle Scholar
  • 25 Ono E, Ariga M, Oshima S. et al. Three novel mutations of the MCT8 (SLC16A2) gene: Individual and temporal variations of endocrinological and radiological features. Clin Pediatr Endocrinol 2016; 25: 23-35
    CrossrefPubMedGoogle Scholar
  • 26 Blackstone C. Chapter 41 – Hereditary spastic paraplegia. In: Geschwind DH, Paulson HL, Klein C. Hrsg Handbook of Clinical Neurology. Elsevier; 2018: 633-652. Im Internet: http://www.sciencedirect.com/science/article/pii/B9780444640765000417
    Google Scholar
  • 27 Gencic S, Abuelo D, Ambler M. et al. Pelizaeus-Merzbacher disease: An X-linked neurologic disorder of myelin metabolism with a novel mutation in the gene encoding proteolipid protein. Am J Hum Genet 1989; 45: 435-442
    PubMedGoogle Scholar
  • 28 Uhlenberg B, Schuelke M, Rüschendorf F. et al. Mutations in the gene encoding gap junction protein α12 (Connexin 46.6) cause pelizaeus-merzbacher–like disease. Am J Hum Genet 2004; 75: 251-260
    CrossrefPubMedGoogle Scholar
  • 29 Pérez-Brangulí F, Mishra HK, Prots I. et al. Dysfunction of spatacsin leads to axonal pathology in SPG11-linked hereditary spastic paraplegia. Hum Mol Genet 2014; 23: 4859-4874
    CrossrefPubMedGoogle Scholar
  • 30 Denton K, Mou Y, Xu C-C. et al. Impaired mitochondrial dynamics underlie axonal defects in hereditary spastic paraplegias. Hum Mol Genet 2018; 27: 2517-2530
    CrossrefPubMedGoogle Scholar
  • 31 Mueller N, Sassa T, Morales-Gonzalez S. et al. De novo mutation in ELOVL1 causes ichthyosis, acanthosis nigricans, hypomyelination, spastic paraplegia, high frequency deafness and optic atrophy. J Med Genet 2019; 56: 164-175
    CrossrefPubMedGoogle Scholar
  • 32 Sherwood NT, Sun Q, Xue M. et al. Drosophila spastin regulates synaptic microtubule networks and is required for normal motor function. PLOS Biol 2004; 2: e429
    CrossrefPubMedGoogle Scholar
  • 33 Kyono Y, Subramani A, Ramadoss P. et al. Liganded thyroid hormone receptors transactivate the DNA methyltransferase 3a gene in mouse neuronal cells. Endocrinology 2016; 157: 3647-3657
    CrossrefPubMedGoogle Scholar
  • 34 Cao X-Y, Jiang X-M, Dou Z-H. et al. Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med 1994; 331: 1739-1744
    CrossrefPubMedGoogle Scholar
  • 35 Zimmermann MB. Iodine deficiency. Endocr Rev 2009; 30: 376-408
    CrossrefPubMedGoogle Scholar
  • 36 Halpern J-P, Boyages SC, Maberly GF. et al. The neurology of endemic cretinism, a study of two endemias. Brain 1991; 114: 825-841
    CrossrefPubMedGoogle Scholar
  • 37 Burrow GN, Fisher DA, Larsen PR. Maternal and Fetal Thyroid Function. N Engl J Med 1994; 331: 1072-1078
    CrossrefPubMedGoogle Scholar
  • 38 Vulsma T, Gons MH, de Vijlder JJM. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989; 321: 13-16
    CrossrefPubMedGoogle Scholar
  • 39 Smith CD, Grondin R, LeMaster W. et al. Reversible cognitive, motor, and driving impairments in severe hypothyroidism. Thyroid 2014; 25: 28-36
    CrossrefPubMedGoogle Scholar
  • 40 Khedr EM, Toony LFE, Tarkhan MN. et al. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology 2000; 41: 88-94
    CrossrefPubMedGoogle Scholar
  • 41 Torres CF, Moxley RT. Hypothyroid neuropathy and myopathy: Clinical and electrodiagnostic longitudinal findings. J Neurol 1990; 237: 271-274
    CrossrefPubMedGoogle Scholar
  • 42 Wémeau JL, Pigeyre M, Proust-Lemoine E. et al. Beneficial effects of propylthiouracil plus l-Thyroxine treatment in a patient with a mutation in MCT8. J Clin Endocrinol Metab 2008; 93: 2084-2088
    CrossrefPubMedGoogle Scholar
  • 43 Groeneweg S, Peeters RP, Visser TJ. et al. Triiodothyroacetic acid in health and disease. J Endocrinol 2017; 234: R99-R121
    CrossrefPubMedGoogle Scholar
  • 44 Kersseboom S, Horn S, Visser WE. et al. In vitro and mouse studies support therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol Endocrinol Baltim Md 2015; me00009999
    CrossrefPubMedGoogle Scholar
  • 45 Di Cosmo C, Liao X-H, Dumitrescu AM. et al. A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology 2009; 150: 4450-4458
    CrossrefPubMedGoogle Scholar
  • 46 Bárez-López S, Obregon MJ, Martínez-de-Mena R. et al. Effect of triiodothyroacetic acid treatment in mct8 deficiency: A word of caution. Thyroid 2015; 26: 618-626
    CrossrefPubMedGoogle Scholar
  • 47 Visser WE, Heuer H, Visser TJ. Triiodothyroacetic acid treatment in MCT8 deficiency: A word of nuance. Thyroid 2016; 26: 615-617
    CrossrefPubMedGoogle Scholar
  • 48 Slavc I, Cohen-Pfeffer JL, Gururangan S. et al. Best practices for the use of intracerebroventricular drug delivery devices. Mol Genet Metab 2018; 124: 184-188
    CrossrefPubMedGoogle Scholar
  • 49 Bárez-López S, Grijota-Martínez C, Liao XH. et al. Intracerebroventricular administration of the thyroid hormone analog TRIAC increases its brain content in the absence of MCT8. PLoS One 2019; 14 (12) e0226017
    CrossrefPubMedGoogle Scholar
  • 50 Iwayama H, Liao X-H, Braun L. et al. Adeno Associated Virus 9–Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. Thyroid 2016; 26: 1311-1319
    CrossrefPubMedGoogle Scholar
  • 51 Finan B, Yang B, Ottaway N. et al. Targeted estrogen delivery reverses the meta-bolic syndrome. Nat Med 2012; 18: 1847-1856
    CrossrefPubMedGoogle Scholar
  • 52 Quarta C, Clemmensen C, Zhu Z. et al. Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity. Cell Metab 2017; 26 (04) 620-632
    CrossrefPubMedGoogle Scholar
  • 53 Finan B, Clemmensen C, Zhu Z. et al. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell 2016; 167 (03) 843-857
    CrossrefPubMedGoogle Scholar
  • 54 Müller TD, Finan B, Bloom SR. et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30: 72-130
    CrossrefPubMedGoogle Scholar
  • 55 Daneman D, Howard NJ. Neonatal thyrotoxicosis: Intellectual impairment and cranio-synostosis in later years. J Pediatr 1980; 97: 257-259
    CrossrefPubMedGoogle Scholar
  • 56 Fischer J, Kleinau G, Müller A. et al. Modulation of monocarboxylate transporter 8 oligomerization by specific pathogenic mutations. J Mol Endocrinol 2015; 54: 39-50
    CrossrefPubMedGoogle Scholar